Major Pharmaceuticals has recalled 12 levothyroxine sodium tablet products distributed nationwide after the FDA classified the action as a Class II recall because the medications were subpotent, according to a July 28 FDA enforcement report. The recall was initiated July 13 and classified July 17.
Subpotent drugs contain less active ingredient than specified on the label, which can reduce the medication’s intended effect. The recalled products include levothyroxine sodium tablets in 25 micrograms, 50 micrograms, 75 micrograms, 88 micrograms, 112 micrograms, 125 micrograms and 150 micrograms strengths packaged in 100-tablet and 10-tablet unit-dose blister cartons. The affected lots have expiration dates ranging from July 2026 through January 2027.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
